Literature DB >> 29374761

Borderline positive antineutrophil cytoplasmic antibodies (ANCA)-PR3/MPO detection in a large cohort tertiary center: lessons learnt from a real-life experience.

Abdulla Watad1,2,3, Nicola L Bragazzi4, Kassem Sharif1,3, Boris Gilburd2, Yarden Yavne1,3, Dennis McGonagle5, Howard Amital1,2,3, Yehuda Shoenfeld2,3.   

Abstract

BACKGROUND: Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence (IIF) are the best strategies for antineutrophil cytoplasmic antibodies (ANCA) detection. In a minority of subjects, ELISA-based ANCA testing may result in a borderline positive titre. Therefore, we assessed the clinical significance of such a result.
METHODS: This is a retrospective study, which included all subjects screened for ANCA subtypes (myeloperoxidase (MPO) or proteinase-3 (PR3)) with subsequent identification of borderline positive results, as determined by ELISA and retested using IIF. The demographic, clinical and laboratory data of subjects with borderline positive ANCA test results were extracted from their medical records.
RESULTS: A total of 14,555 PR3/MPO-ANCA tests were performed with ELISA during the study period (2006-2016). Of the 14,555 PR3-ANCA antibody tests that were performed, 94 were borderline positive (titre 0.9-1.1), and of 14,555 MPO-ANCA antibody tests, 43 were borderline positive (titre 0.9-1.1). The male-to-female ratio was 1:1.08 and the mean age was 50.95±21.79 years. Four MPO-ANCA (9.30%) and 11 PR3-ANCA (11.70%) antibody borderline samples resulted positive on IIF testing. Subjects with borderline positive MPO-ANCA were found to have a poorer outcome in terms of renal failure and the requirement of dialysis.
CONCLUSIONS: Subjects with borderline positive MPO-ANCA and positive p-ANCA (IIF) seem to have a less favorable outcome. Physicians should be aware of these findings and possibly perform a closer follow-up and routine screening for these subjects.

Entities:  

Keywords:  ANCA; ELISA; c-ANCA; immunofluorescence; myeloperoxidase; p-ANCA; proteinase-3; vasculitis

Mesh:

Substances:

Year:  2018        PMID: 29374761     DOI: 10.1515/cclm-2017-1053

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  1 in total

Review 1.  Real-world evidence in rheumatic diseases: relevance and lessons learnt.

Authors:  Durga Prasanna Misra; Vikas Agarwal
Journal:  Rheumatol Int       Date:  2019-02-06       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.